ACRV · Acrivon Therapeutics, Inc.
Market Cap
$72.60M
Shares
42.85M
Volume · Oct 19
122.27K
Avg daily vol (3M)
316.1K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.69
Open$1.68
Day$1.63–1.74
52W close$1.29–3.01
Avg vol 30d302K
Short int1.6M · 3.8% float · 4.4d
Short vol47%
Last earningsMay 26, 2026
DataNov 2022–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 23, 2026
Est · unconfirmed
· in 5 wks
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$74.22M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-91.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$89.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.8%
Year over year · more shares
Price change (1Y)
-12.3%
Trailing year
Short interest
3.8%
Latest settlement · 4.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−14%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−11%
trailing
YTD return
−30%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +6 funds added
Insider flow
Distributing
Net -$39.4K over 90 days · 100% sells
Short interest
Rising
3.77% of float · ▲ +34.4% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
46 holders — mid 3-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
EPS growth
+15%
Y/Y
Free cash flow
$-65.3M
Balance sheet
$41.5M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +6 funds added
Insider flow
Distributing
Net -$39.4K over 90 days · 100% sells
Short interest
Rising
3.77% of float · ▲ +34.4% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
46 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 23%
Range high $3
vs 200-day avg -5%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACRV
this stock
Acrivon Therapeutics, Inc.
|
$72.60M | -29.9% | — | — | 3.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +1.3% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACRV | -11.1% | -15.9% | -11.1% | -17.6% | -29.9% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -9.6% | -15.0% | -18.8% | -18.1% | -42.3% |